Education
About Us
Working with TipRanks
Follow Us
Orasure (OSUR)
:OSUR
OSUR Stock Chart & Stats
$2.38
-$0.09(-2.38%)
At close: 4:00 PM EST
$2.38
-$0.09(-2.38%)
Day’s Range― - ―
52-Week Range$2.08 - $4.22
Previous CloseN/A
Volume226.53K
Average Volume (3M)750.47K
Market Cap
$176.46M
Enterprise Value$31.33M
Total Cash (Recent Filing)$216.48M
Total Debt (Recent Filing)$13.46M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 03, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding71,733,530
10 Day Avg. Volume668,638
30 Day Avg. Volume750,469
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.65
Price to Sales (P/S)1.45
P/FCF Ratio11.40
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.62
Enterprise Value/Ebitda-0.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.86
Revenue Forecast (FY)$117.18M
Orasure Technologies News
OSUR FAQ
What was Orasure’s price range in the past 12 months?
Orasure lowest stock price was $2.08 and its highest was $4.22 in the past 12 months.
What is Orasure’s market cap?
Orasure’s market cap is $176.46M.
When is Orasure’s upcoming earnings report date?
Orasure’s upcoming earnings report date is Mar 03, 2026 which is in 74 days.
How were Orasure’s earnings last quarter?
Orasure released its earnings results on Nov 05, 2025. The company reported -$0.19 earnings per share for the quarter, the consensus estimate of -$0.19 by $0.
Is Orasure overvalued?
According to Wall Street analysts Orasure’s price is currently Overvalued.
Does Orasure pay dividends?
Orasure does not currently pay dividends.
What is Orasure’s EPS estimate?
Orasure’s EPS estimate is -0.21.
How many shares outstanding does Orasure have?
Orasure has 71,733,530 shares outstanding.
What happened to Orasure’s price movement after its last earnings report?
Orasure reported an EPS of -$0.19 in its last earnings report, expectations of -$0.19. Following the earnings report the stock price went down -6.615%.
Which hedge fund is a major shareholder of Orasure?
Currently, no hedge funds are holding shares in OSUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
OSUR Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 109.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.43%
12-Months-Change
Fundamentals
Return on Equity
-15.30%
Trailing 12-Months
Asset Growth
-8.83%
Trailing 12-Months
Company Description
Orasure
OraSure Technologies, Inc. is a leader in the field of oral fluid diagnostics and medical devices, primarily focusing on the development and sale of products for the detection of infectious diseases and for drug testing. The company operates in two main sectors: the infectious disease testing market and the substance abuse testing market. Its core products include rapid diagnostic tests for HIV, HCV, and other infectious diseases, as well as oral fluid collection devices used for drug testing and other applications.
OSUR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted OraSure's strategic initiatives, such as the acquisition of BioMedomics and the renewal of important public health programs. However, the call also addressed significant revenue declines in both U.S. and International Diagnostics segments and continued financial losses, indicating a challenging year ahead.View all OSUR earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―
Ownership Overview
4.98% Insiders
16.94% Mutual Funds
30.31% Other Institutional Investors
35.24% Public Companies and
Individual Investors